Abstract: Clinical and Prognostic Analysis of 100 Patients with NeuroblastomaZhongyuan LI, Qiang ZHAO, JingfuWANG, Yanna CAO, Zhanglin LI, Jie YANCorrespondence to: Qiang ZHAO, E-mail: qiangzhao169@yahoo.com.cnDepartment of Pediatric Oncology, Tianjin Medical University Cancer Institute and Hospital，Key Laboratory of Cancer Preventionand Therapy, Tianjin 300060, ChinaAbstract Objective: To investigate the clinical features, treatment and prognostic factors of patients with neuroblastoma. Meth-ods: Clinical data of 100 patients with neuroblastoma with extensive follow-up, treated in our department between April 1995 and Au-gust 2009, were retrospectively analyzed and the prognostic factors were evaluated. Results: After a median follow-up of 26.6 months (ranged 2 to 161 months ), 33 cases had complete remission (CR) (median 14.4 months) and 20 cases had stable disease, with an overallsurvival rate ( SR ) of 53%. The 1-, 2-, and 5-year overall survival rates of the 100 patients were 93.5%, 81.5% and 33.6%, respectively.Univariate analysis revealed that the presence of tumor growing outside the mediastinum, INSS stage Ⅲ＋Ⅳ, NSE > 100 μg/L, LDH >700 U/L, metastasis outside of the bone marrow, surgery and pathological type were prognostic factors. Multivariate analysis revealedthat the presence of tumor growing outside of the mediastinum, tumor resectability and LDH > 700 U/L were independent prognosticfactors. Conclusion: The prognosis for patients with neuroblastoma within the mediastinum is better than that for patients with neuro-blastoma elsewhere in the body. Patients with neuroblastoma should be treated with combined therapy that includes surgery, radiothera-py and chemotherapy. Complete resection of the tumor significantly improves the prognosis. Detecting serum LDH level contributes tothe determination of the prognosis for neuroblastoma patients.Keywords Neuroblastoma; Clinical characteristics; Combined modality therapy; Prognosis